Johnson & Johnson (J&J, NYSE: JNJ)’s pulmonary hypertension treatment, Opsumit (macitentan), is set to encounter intensified competition in China following the approval of a generic version by local pharmaceutical company Qilu Pharmaceutical last month.
Macitentan, classified as an endothelin receptor antagonist (ERA), initially received marketing approval in the US in October 2013, and subsequently in China in September 2017. It was incorporated into China’s National Reimbursement Drug List in 2019. The drug stands out as the sole targeted therapy with evidence suggesting the ability to reverse right ventricular remodeling, a significant benefit as it can substantially slow disease progression, enhance the quality of life for patients, and reduce mortality rates associated with pulmonary hypertension.- Flcube.com
